Small-cap stocks in the Russell 2000 (^RUT) can be a goldmine for investors looking beyond the usual large-cap names. But with less stability and fewer resources than their bigger counterparts, these companies face steeper challenges in scaling their businesses.

Healthcare stocks were higher late Tuesday afternoon, with the NYSE Healthcare Index and the State S

When Wall Street turns bearish on a stock, it’s worth paying attention. These calls stand out because analysts rarely issue grim ratings on companies for fear their firms will lose out in other business lines such as M&A advisory.

Haemonetics stock has delivered a strong 69.0% return over the past year, yet the valuation signals are mixed, with an intrinsic value estimate based on a Discounted Cash Flow (DCF) model suggesting the shares trade at a discount, while traditional market multiples lean the other way. Haemonetics has returned 69.0% over the past year, which puts more focus on whether the recent share price strength is backed by fundamentals. Expectations for continued revenue growth from its plasma and...

Haemonetics (HAE) has drawn fresh attention after reporting first quarter fiscal 2027 results, with sales of US$339.38 million and net income of US$33.01 million, alongside a US$391.25 million shelf registration tied to an ESOP related stock offering. See our latest analysis for Haemonetics. Haemonetics’ recent earnings beat, higher revenue guidance and fresh clinical data around VASCADE MVP XL have coincided with a strong 90 day share price return of 61.31%. The 1 year total shareholder...

Haemonetics delivered a Q2 performance that surpassed Wall Street’s revenue and adjusted earnings expectations, supported by consistent execution across its business lines. Management attributed the quarter’s results to strong innovation and commercial momentum, particularly in Plasma and Interventional Technologies, where new product rollouts like Persona PLUS and VASCADE MVP XL drove adoption and utilization. CEO Christopher Simon specifically highlighted, "All three of our core platforms cont

Haemonetics raises fiscal 2027 revenue guidance after Q1 earnings and sales beat, supported by Plasma growth and stronger cash generation.

Plasma disposables surged 25% as Persona PLUS adoption accelerated globally.

Examine Haemonetics' (HAE) international revenue patterns and their implications on Wall Street's forecasts and the prospective trajectory of the stock.

Blood products company Haemonetics (NYSE:HAE) beat Wall Street’s revenue expectations in Q2 CY2026, with sales up 5.6% year on year to $339.4 million. Its non-GAAP profit of $1.14 per share was 5.8% above analysts’ consensus estimates.

Haemonetics (NYSE:HAE) reported a stronger start to fiscal 2027, with first-quarter revenue rising 6% year over year to $339 million and adjusted diluted earnings per share increasing 4% to $1.14. The company raised its full-year revenue outlook, citing broad-based growth across its MedSurg and aphe

Moby summary of Haemonetics Corporation's Q1 2027 earnings call

Revenue up 6% with robust plasma and vascular closure growth, offsetting margin pressures and external cost headwinds.

Haemonetics (HAE) delivered earnings and revenue surprises of +6.54% and +3.49%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Blood products company Haemonetics (NYSE:HAE) reported Q2 CY2026 results beating Wall Street’s revenue expectations, with sales up 5.6% year on year to $339.4 million. Its non-GAAP profit of $1.14 per share was 5.8% above analysts’ consensus estimates.

Perrigo (PRGO) delivered earnings and revenue surprises of +61.29% and +1.89%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Haemonetics recently reported results from a large Emory University retrospective study of 1,623 patients, showing its VASCADE MVP XL venous vascular closure system delivered rapid hemostasis, high same-day discharge rates and low complication rates in large-bore sheath electrophysiology procedures. This new real-world evidence, coming after the FDA’s March 2026 expanded labeling for VASCADE MVP XL up to 17F outer diameter sheaths, strengthens the product’s clinical and procedural...

Haemonetics (HAE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

A company that generates cash isn’t automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand.

Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Those leading the charge have realized strong financial performance, and over the past six months, the industry’s 10% return has closely followed the S&P 500.

Investors looking for hidden gems should keep an eye on small-cap stocks because they’re frequently overlooked by Wall Street. Many opportunities exist in this part of the market, but it is also a high-risk, high-reward environment due to the lack of reliable analyst price targets.